Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
CNY PRC Accounting Standards / consolidated
1,222,248,593.56
203,867,316.47 Net income attributable to shareholders of the listed company
Consolidated group financials; not standalone CRO/CDMO segment revenue.
Source unit: CNY.
2026Q3 (YTD) · Reporting notes
The latest report covers January–September 2026 year to date, not the third quarter alone; unaudited quarterly report.
Consolidated group financials; not standalone CRO/CDMO segment revenue.
Source unit: CNY.
Earnings include a loss or a negative prior-period base. Any source-reported year-over-year percentage retains the source definition and is not interpreted as conventional positive earnings growth.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Clinical bioanalysis and bioequivalence services
Specialist contract research/testing services
Combines CRO services with proprietary drug development; services span discovery, pharmacology, CMC, clinical research, and bioanalysis.
Listed as SSE 688621; original 2025 annual and 2026Q3 (YTD) reports reviewed.
Program / service
Target / indication
Representative stage
Evidence & scope
Preclinical-to-clinical CRO / proprietary drug R&D
Not applicable (services/platform) · Drug research and manufacturing services for clients
Services / platform
Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
A Bioanalysis paper describes development and prevalidation of a Luminex xMAP assay for simultaneous domain-specific anti-drug antibody detection. Using PEGylated Cas9 as a model, the authors report adjustable bead ratios and on-demand coupling to accommodate different minimum required dilutions. The original abstract supports assay feasibility, rather than universal validation across multidomain therapeutics or demonstrated clinical benefit.
Labcorp published a conference-poster summary on independent RNA and DNA integrity assessment in cell and gene therapy bioanalysis. It evaluates Agilent TapeStation microfluidic electrophoresis as an orthogonal quality-control tool alongside qPCR and RT-qPCR, which do not directly measure overall integrity. The public summary describes the evaluation's objective and rationale, without quantitative performance results or peer-reviewed publication metadata.
Service-provider record; no proprietary drug pipeline implied. Confirm laboratory qualification and project suitability.
Financials are consolidated figures for the listed group. Revenue by service line, available capacity, and project fit require further verification at the segment and operating-entity levels.
Proprietary products/licensing and research services operate in parallel. Distinguish business lines; group profit does not establish the quality of a specific service.
